June 6, 2022Open Access

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

BMBradley J. MonkFlorida Cancer Specialists & Research Institute CPChristine ParkinsonNational Health Service MLMyong Cheol LimGynecologic Oncology Group

Key Points

Key points are not available for this paper at this time.

Abstract

Rucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.

KI fragen

Bookmark

View Full Paper

Cite This Study

Monk et al. (Mon,) studied this question.

synapsesocial.com/papers/69d835a9f4e559c61eae2e43 https://doi.org/https://doi.org/10.1200/jco.22.01003

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1On generalized fixed sequence procedures for controlling the FWER2015 · 2 citations
2Joint ENGOT and GOG Foundation requirements for trials with industry partners2019 · 13 citations
3Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial2016 · 1,208 citations
4ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer2021 · 92 citations
5Untitled185 citations

KI fragen

Bookmark

View Full Paper